Sami Inkinen from Virta is trying to cure the world from Type 2 Diabetes forever. An experienced founder, Sami Inkinen founded and exited Trulia, a real estate property listing company. Trulia was bought by Zillow for about US$3.5 billion back in 2014. Now, we are inspired by his desire to fight against Type 2 Diabetes. You can read more about Diabetes at CuraHOPE here.
One Man Trying To Fight And Cure Type 2 Diabetes Forever
What was exciting in the report on TechCrunch was the results which was claimed by Virta. The company claimed that in a small trial involving 262 people, 91% of the people participating in the trial finished the program, and an 87% either reduce or stop their dosage of insulin. This is apparently done through a low-carb diet, through a nutritionally planned diet which helps to reverse type 2 Diabetes. Essentially, Virta is trying to help patients through lifestyle changes.
We are particularly inspired by what Sami is trying to do. This guy had no prior background in medical science, does not suffer from Diabetes, and was both active and healthy, yet being told he was pre-diabetic.
That sparked off his intense desire to learn what exactly caused Diabetes, and he found out that what he is trying to do now to cure type 2 Diabetes has been published in medical papers for more than 30 years!
The drugs to control Diabetes average around US$500 every month. Imagine the significance of this claim! Pharmaceutical companies have been selling various kinds of drugs to control Diabetes and perhaps this might be a right time to question ourselves, have we trusted merchants too much? If we do our research before buying things (such as cars, houses and electronic goods), why shouldn’t we do the same for drugs we are taking into our body?
A Good Wake Up Call
This is a good wake up call for all of us, who are taking one form of drug or another to fight against incurable and chronic diseases. Do not let published reports and the media sway you, find out the results behind clinical trials and question everything.